AccurKardia
AccurKardia is an ECG-led diagnostics software company focused on transforming ECG data into a more powerful diagnostic tool and broad biomarker to improve patient outcomes and save lives globally. With initial applications in cardiology, the company offers transformative, cloud-based diagnostic tools, including AccurECG™, an FDA-cleared Class II software as a medical device (SaMD) for fully automated, near real-time ECG interpretation. AccurKardia’s AK+ Guard™—an AI-driven hyperkalemia detection solution using Lead I ECG data to help patients with conditions like CKD and ESRD identify life-threatening high potassium levels earlier—received FDA Breakthrough Device Designation and was accepted into the FDA Total Product Life Cycle (TAP) Advisory Program in December 2024. The company’s aortic stenosis detection model, AK-AVS™, received FDA Breakthrough Device Designation in October 2024. AccurKardia completed the 2024 Cohort of MedTech Innovator (MTI) and was one of five companies selected for the inaugural American Heart Association’s Heart and Brain Health Accelerator track within MTI.
AccurKardia
AccurKardia is an ECG-led diagnostics software company focused on transforming ECG data into a more powerful diagnostic tool and broad biomarker to improve patient outcomes and save lives globally. With initial applications in cardiology, the company offers transformative, cloud-based diagnostic tools, including AccurECG™, an FDA-cleared Class II software as a medical device (SaMD) for fully automated, near real-time ECG interpretation. AccurKardia’s AK+ Guard™—an AI-driven hyperkalemia detection solution using Lead I ECG data to help patients with conditions like CKD and ESRD identify life-threatening high potassium levels earlier—received FDA Breakthrough Device Designation and was accepted into the FDA Total Product Life Cycle (TAP) Advisory Program in December 2024. The company’s aortic stenosis detection model, AK-AVS™, received FDA Breakthrough Device Designation in October 2024. AccurKardia completed the 2024 Cohort of MedTech Innovator (MTI) and was one of five companies selected for the inaugural American Heart Association’s Heart and Brain Health Accelerator track within MTI.